Floatz logo

Siponimod

Multiple Sclerosis, Relapsing-Remitting

Novartis PharmaceuticalsSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
81/ 100

Competitive context

79 Active assets in the Multiple Sclerosis, Relapsing-Remitting cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4A
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Natalizumab
Biogen
Phase 4BBB
Interferon ?1 (human fibroblast protein moiety)
Biogen
Phase 4BBB
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER
University Hospital, Montpellier
Phase 4BBB

View all 50 →

Same molecule, other indications

Siponimod is also rated in:

secondary progressive multiple sclerosisDormant
BBB
Indicative ·
75 / 100
View asset →
hemorrhagic strokeDormant
B
Indicative ·
57 / 100
View asset →
intracerebral hemorrhageDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →